Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

Bliss GVS Pharma, a small-cap player in the pharmaceuticals and drugs industry, has recently reached a new 52-week high of Rs. 181.35 on January 1, 2025. The stock has shown strong performance, outperforming its sector by 7.79% today. Over the past six days, Bliss GVS Pharma has experienced consecutive gains, accumulating a total return of 11.29%.

The stock’s intraday high of Rs. 181.35 reflects a 10.14% increase for the day. Additionally, Bliss GVS Pharma is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.

In terms of annual performance, Bliss GVS Pharma has delivered a notable return of 42.53% over the past year, significantly outpacing the Sensex, which has recorded an 8.20% increase during the same period. The stock’s recent performance highlights its resilience and growth within the competitive pharmaceuticals sector.

Related Posts

  • Pharma
  • May 14, 2025
  • 84 views
DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

The Drugs Technical Advisory Board (DTAB) has directed the Central drug regulator to take up the matter related to withdrawal of product license for antibiotic fixed dose combinations (FDCs), which…

  • Pharma
  • May 14, 2025
  • 91 views
India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

India’s anti-obesity drug market has grown more than fourfold in the last five years fuelled by rising instances of lifestyle diseases along with greater affordability and willingness among a section…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

3 held with 60,000 tramadol tablets

3 held with 60,000 tramadol tablets

Indian Pharma May See Limited Short-Term Impact from US Drug Pricing Order

Indian Pharma May See Limited Short-Term Impact from US Drug Pricing Order